APONVIE® Recognized in Updated Guidelines for PONV Management
Heron Therapeutics, Inc. (Nasdaq: HRTX), a leading biotechnology firm, has achieved a significant milestone with the inclusion of APONVIE® (aprepitant) injectable emulsion in the latest Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV). This recognition emphasizes APONVIE as a critical therapeutic option for the prevention of PONV, underscoring its pivotal role in enhancing patient care.
Understanding PONV and Its Challenges
PONV is a concern that affects approximately 30% of patients undergoing surgery, and this figure can surge to a staggering 80% in high-risk groups. The impact of PONV extends beyond discomfort, leading to significant dissatisfaction among patients who view postoperative vomiting as one of the most undesirable complications. The updated guidelines highlight the necessity of effective solutions to tackle this prevalent issue.
APONVIE's Unique Features
APONVIE stands out as the sole FDA-approved intravenous formulation of a neurokinin-1 (NK-1) receptor antagonist. Its formulation allows for a rapid onset of action through a 30-second IV administration, providing a faster alternative compared to oral aprepitant. Its long half-life not only facilitates immediate relief but also helps extend protective benefits against nausea and vomiting after surgery, which is crucial for patient recovery.
Effective Strategies for PONV Prevention
The updated PONV guidelines advocate for a structured approach to managing PONV risk. Using APONVIE as part of a multimodal strategy can significantly minimize the chances of PONV occurrence. Clinical evidence showcased in the guidelines indicates that aprepitant alone or in combination therapy is more effective than traditional 5-HT3 receptor antagonists for preventing postoperative vomiting.
The Importance of Post-Discharge Management
Post-discharge nausea and vomiting (PDNV) pose a considerable risk for recently discharged surgical patients. The guidelines recommended using long-acting antiemetics like APONVIE before discharge, ensuring patients leave with adequate protection from nausea which can enhance their recovery experience at home.
Insights from Industry Leaders
Craig Collard, CEO of Heron Therapeutics, expressed enthusiasm about the guidelines, stating, “The release of the PONV Guidelines comes at a defining moment for surgical care. More procedures than ever are being performed in outpatient and short-stay settings...” His comments reflect the critical nature of preventing PONV, which is essential for supporting patients' safe and comfortable recovery.
Kevin Warner, Senior Vice President at Heron, reinforced the need for ongoing vigilance regarding PONV management after discharge. He noted that the guidelines empower clinicians to recognize patients at risk of PONV and promote the necessary precautions to facilitate smoother recoveries post-surgery.
About APONVIE and Its Role
APONVIE is a neurokinin-1 receptor antagonist specifically designed for preventing PONV. Delivered via a swift IV push, a single 32 mg dose of APONVIE has proven bioequivalence to a 40 mg oral dose of aprepitant, demonstrating its capability to achieve therapeutic levels rapidly. This product was officially approved by the FDA and became available for commercial distribution, reflecting Heron Therapeutics' commitment to advancing patient care.
Heron Therapeutics' Commitment to Innovation
Heron Therapeutics, Inc. prioritizes innovative solutions aimed at enhancing the quality of care for patients. With a robust pipeline of therapeutic products and advancements in biotechnology, Heron strives to set a new standard of care, particularly in the realms of acute care and oncology.
Frequently Asked Questions
What is PONV, and why is it significant?
PONV stands for postoperative nausea and vomiting, a condition affecting many patients after surgery, impacting their recovery and satisfaction.
How does APONVIE work?
APONVIE functions as a neurokinin-1 receptor antagonist, preventing nausea and vomiting by blocking specific signals in the body.
What are the benefits of using APONVIE?
APONVIE offers rapid administration, a long half-life, and proven effectiveness, particularly in preventing postoperative vomiting compared to other medications.
What guidelines recognize APONVIE?
APONVIE is included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting, highlighting its significance in PONV prevention.
How can healthcare providers utilize the PONV guidelines?
Healthcare providers can use the guidelines to assess PONV risk and implement multimodal prophylaxes strategies, improving patient outcomes during recovery.
